Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Improving global accessibility of myeloma treatment

Noopur Raje • 11 Sep 2021
IMW 2021
Multiple Myeloma CAR-T

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, talks on improving the accessibility of treatment for patients with myeloma worldwide, highlighting the global efforts from organizations such as the International Myeloma Society to make treatments like chimeric antigen receptor (CAR) T-cell therapy available globally. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Noopur Raje, MD, has participated in consulting for Amgen, BMS, GSK, Janssen, Takeda, Oncopeptides, Karyopharm, Bluebird Bio, Pfizer, AstraZeneca; has participated in the advisory boards of Immuneel and Caribou; and has received research funding from Bluebird Bio,

More from Noopur Raje

2:06
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma
Noopur Raje • 29 Sep 2023
2:35
Recommendations for managing infections in patients with myeloma treated with bispecifics
Noopur Raje • 29 Sep 2023
1:13
The role of checkpoint inhibitors in multiple myeloma & future considerations for these agents
Noopur Raje • 29 Sep 2023
2:17
Session highlights: practical aspects of immunotherapy in multiple myeloma
Noopur Raje • 29 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals